Production of Viral Glycoproteins in Genetically Engineered Mammalian Cell Lines for Use as Vaccines against Herpes Simplex Virus and the Acquired Immune Deficiency Syndrome Retrovirus
One promise of recombinant DNA technology is the possibility of developing new and improved vaccines to prevent the transmission of infectious diseases. Using these techniques, it is possible to produce virtually unlimited quantities of the surface antigens of pathogenic organisms without resorting to the large-scale culture of the pathogen itself. Conventional methods of vaccine production (i.e., live attenuated viruses, killed viruses, or extracts of killed viruses) are limited by the fact that some pathogens are difficult or uneconomical to grow. In addition, society is still haunted by fears that such vaccine preparations could be contaminated by unattenuated or inadequately inactivated virus. Even when the most stringent production methods are applied, manufacturers must be concerned with the possibility that a vaccine could induce latent infections, oncogenic transformation, or autoimmunity. The recombinant DNA approach to vaccine development circumvents these problems by providing a preparation consisting of a single highly purified protein, derived from a safe noninfectious source.
KeywordsAcquire Immune Deficiency Syndrome Apparent Molecular Weight Genital Herpes Hydrophobic Domain Recombinant Vaccine
Unable to display preview. Download preview PDF.
- Coffin, J., Haase, A., Levy, J. A., Montagnier, L., Orosziam, S., Teick, N., Temin, H., Toyoshima, K., Varmus, H., Vogt, P., Weiss, R. (1986). Nature (Lond.) 321, 10.Google Scholar
- Kern, E. R., Vogt, P. E., Gregory, T., Lasky, L. A., and Berman, P. W. (1987). J. Virol, (in press).Google Scholar
- Lasky, L. A., Dowbenko, D., Simonsen, C. C, and Berman, P. W. (1984). Bio /Technology 2, 527–532.Google Scholar
- Staal, F. W., and Gallo, R. C. (1985). Blood 65, 253–263.Google Scholar